JPRN-jRCT2080222339已完成3 期
A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase 3 Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Advanced gastric cancer (including GEJ) that has progressed following first-line therapy.
- •- Privision of tumour sample (from either a resection or biopsy).
- •- At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline and following up visits.
排除标准
- •- More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with more than 6 month wash out period) for the treatment of gastric cancer in the advanced setting.
- •- Any previous treatment with a PARP inhibitor, including olaparib.
- •- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for 5 years or more.
- •- HER2 positive patients
研究者
相似试验
进行中（未招募）
1 期
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyEarly non-metastatic breast cancer and therapy-induced bone loss and fracturesMedDRA version: 21.1Level: PTClassification code 10065687Term: Bone lossSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 100000004864EUCTR2005-005275-15-ATAmgen Limited3,400
进行中（未招募）
1 期
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyEarly non-metastatic breast cancer and therapy-induced bone loss and fracturesMedDRA version: 21.1Level: PTClassification code 10065687Term: Bone lossSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 100000004864EUCTR2005-005275-15-SEAmgen Limited3,400
已完成
不适用
enzilumab Study in Healthy Korean SubjectsCodes for special purposesKCT0006851Telcon RF Pharmaceuticals20
已完成
不适用
A human study to Investigate the Effect of L.lactis CKDB001 Administration on Liver Aminotransferases in Subjects with Nonalcoholic Fatty Liver DiseaseKCT0007388Chong Kun Dang Bio120
尚未招募
不适用
A Randomized, Double-blinded, Placebo-controlled, Multi-center Phase 2 Study to Explore the Efficacy and Safety of Subcutaneous Injection EG-Myocin Immediately Before and After PCI in Patients with Acute ST-Elevation Myocardial Infarction (STEMI)KCT0004288Eyegene60